The primary charge of the Food and Drug Administration is to safeguard the health and well-being of the public through the application of scientifically sound regulatory activities. The complexity of the FDA's mission is rapidly increasing, with a growing number of food and drug products requiring regulation in the context of rapid evolution of the scientific landscape. These changes pose unprecedented challenges, and opportunities, to ensure that processes and protocols are adopted that reflect innovative and efficient methods of fulfilling the FDA's charge. Partnerships with academic institutions provide these institutions a valued opportunity to work directly with regulators to fulfill the FDA's mission while simultaneously providing the Agency opportunities for access and exposure to advanced scientific exchange and training as well as specific intellectual expertise and human capital focused on the FDA's priority areas. We propose a Johns Hopkins - FDA Collaborating Center of Excellence in Regulatory Science and Innovation (CERSI) that will ensure the FDA remains a standard- bearer in regulatory science. Our CERSI leverages the geographic proximity and extensive relationship between our institutions and uses this as a foundation to develop new training opportunities and to promote a programmatic focus on three priority areas for the agency: (1) improving clinical studies and evaluation; (2) strengthening the social and behavioral science to support informed decisions; and (3) developing a new prevention-focused food safety system. In addition to a strong foundation of collaboration with the Agency, which includes an active Memorandum of Understanding, our partnership will also have many other strengths, including: internationally renowned scholarship in regulatory science; innovative training through online platforms harnessing modern technologies; a nimble and organic operational approach; and the potential for self-sustaining programs that will continue to serve the FDA's strategic mission beyond the time frame of the proposed award.

Public Health Relevance

During the past decade the FDA has made great strides in strengthening its regulatory science activities, yet many opportunities remain. We propose a unique partnership between the FDA and Johns Hopkins University that will produce innovative training and scientific exchange focused on three strategically important areas of FDA regulation: improving clinical studies and evaluation; strengthening the social and behavioral science to support informed decisions; and developing a new prevention-focused food safety system.

Agency
National Institute of Health (NIH)
Institute
Food and Drug Administration (FDA)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01FD004977-02S1
Application #
9133813
Study Section
Special Emphasis Panel (ZFD1-SRC (99))
Project Start
2014-04-15
Project End
2016-03-31
Budget Start
2015-04-01
Budget End
2016-03-31
Support Year
2
Fiscal Year
2015
Total Cost
$100,000
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Mayo-Wilson, Evan; Heyward, James; Keyes, Anthony et al. (2018) Clinical trial registration and reporting: a survey of academic organizations in the United States. BMC Med 16:60
Janssen, Ellen M; Hauber, A Brett; Bridges, John F P (2018) Conducting a Discrete-Choice Experiment Study Following Recommendations for Good Research Practices: An Application for Eliciting Patient Preferences for Diabetes Treatments. Value Health 21:59-68
Ogasawara, Ken; Breder, Christopher D; Lin, Dora H et al. (2018) Exposure- and Dose-response Analyses in Dose Selection and Labeling of FDA-approved Biologics. Clin Ther 40:95-102.e2
Secora, Alex; Alexander, G Caleb; Ballew, Shoshana H et al. (2018) Kidney Function, Polypharmacy, and Potentially Inappropriate Medication Use in a Community-Based Cohort of Older Adults. Drugs Aging 35:735-750
Tieu, Carolyn; Lucas, Eleanor J; DePaola, Mindi et al. (2018) Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review. PLoS One 13:e0195012
Leibler, J H; Dalton, K; Pekosz, A et al. (2017) Epizootics in Industrial Livestock Production: Preventable Gaps in Biosecurity and Biocontainment. Zoonoses Public Health 64:137-145
Hollin, Ilene L; Peay, Holly L; Apkon, Susan D et al. (2017) Patient-centered benefit-risk assessment in duchenne muscular dystrophy. Muscle Nerve 55:626-634
Huang, Emily J; Fang, Ethan X; Hanley, Daniel F et al. (2017) Inequality in treatment benefits: Can we determine if a new treatment benefits the many or the few? Biostatistics 18:308-324
Janssen, Ellen M; Bridges, John F P (2017) Art and Science of Instrument Development for Stated-Preference Methods. Patient 10:377-379
Janssen, Ellen M; Segal, Jodi B; Bridges, John F P (2016) A Framework for Instrument Development of a Choice Experiment: An Application to Type 2 Diabetes. Patient 9:465-79

Showing the most recent 10 out of 11 publications